| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6977253 | VALIDUS PHARMS | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(7 months from now) | |
Equetro is owned by Validus Pharms.
Equetro contains Carbamazepine.
Equetro has a total of 1 drug patent out of which 0 drug patents have expired.
Equetro was authorised for market use on 10 December, 2004.
Equetro is available in capsule, extended release;oral dosage forms.
Equetro can be used as the recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response..
The generics of Equetro are possible to be released after 19 May, 2024.
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 10 December, 2004
Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
EQUETRO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic